- Cassava Sciences (NASDAQ:SAVA) is an after-hours jumper, up 26.3% postmarket on heavy volume after getting a vote of confidence via a Street-high price target from Cantor Fitzgerald.
- The firm set its target to $24, implying a healthy 172% upside.
- It's citing the promise of its first-in-class filamin A chaperone sumifilam, an approach to improve the function of multiple brain receptors to treat Alzheimer's and other neurodegenerative diseases.
- https://seekingalpha.com/news/3625175-cassava-sciencesplus-26-rates-street-high-target-from-cantor
Friday, October 23, 2020
Cassava Sciences rates Street-high target from Cantor
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.